Estrella Immunopharma, Inc.
Biological Products, (No Diagnostic Substances) · EMERYVILLE · CA
Moderate confidence (50%)
Updated Oct 19, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Estrella Immunopharma, Inc. received a delisting notice from its exchange (Sep 1, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Estrella Immunopharma, Inc. received a delisting notice from its exchange
Sep 1, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 1, 2026, Estrella Immunopharma, Inc. (the Company ) received a written notification (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the market value of the Company s listed securities ( MVLS ) was below $35,000,000 for 30 consecutive business days from July 21, 2026 through August 31, 2026, the Company no longer complies with the minimum MVLS requirement for continued listing on The Nasdaq Capita…”
Estrella Immunopharma, Inc. received a delisting notice from its exchange
Aug 17, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, Estrella Immunopharma, Inc. (the Company ) received a written notification (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the closing bid price of the Company s common stock, par value $0.0001 per share (the Common Stock ), was below $1.00 per share for 30 consecutive business days from July 6, 2026 through August 14, 2026, the Company no longer complies with the $1.00 minimum bid price r…”
Estrella Immunopharma, Inc. received a delisting notice from its exchange
Jan 7, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 7, 2026, Estrella Immunopharma, Inc. (the Company ) received a letter (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. The Letter also referenced the compliance plan procedures under Nasdaq Listing Rule 5810(c)(2)(G). The Letter states that the C…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Biological Products, (No Diagnostic Substances)
- Subindustry
- —
- Listing
- SEC lists the tickers ESLA and ESLAW on Nasdaq.
- SEC CIK
- 0001844417
- Website
- —
- —
- Headquarters
- EMERYVILLE, CA
- Also known as
- TradeUP Acquisition Corp.
- Legal entities
- Estrella Immunopharma, Inc.
Sources
Every material source used to build this profile.
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 1, 2026, Estrella Immunopharma, Inc. (the Company ) received a written notification (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the market value of the Company s listed securities ( MVLS ) was below $35,000,000 for 30 consecutive business days from July 21, 2026 through August 31, 2026, the Company no longer complies with the minimum MVLS requirement for continued listing on The Nasdaq Capita…
View source recordSEC Company Submissions (TIER 1 · UNVERIFIED)
Estrella Immunopharma, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — EMERYVILLE, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 7, 2026, Estrella Immunopharma, Inc. (the Company ) received a letter (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a) because the Company has not held an annual meeting of shareholders within the required time period. The Letter also referenced the compliance plan procedures under Nasdaq Listing Rule 5810(c)(2)(G). The Letter states that the C…
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, Estrella Immunopharma, Inc. (the Company ) received a written notification (the Letter ) from the Listing Qualifications Department of The Nasdaq Stock Market LLC ( Nasdaq ) indicating that, because the closing bid price of the Company s common stock, par value $0.0001 per share (the Common Stock ), was below $1.00 per share for 30 consecutive business days from July 6, 2026 through August 14, 2026, the Company no longer complies with the $1.00 minimum bid price r…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:35 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 13, 2026, 12:04 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:36 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.